Dashboard
Manage Tickers

VSTM


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

verastem-reveals-preliminary-data-from-the-first-two-dose-levels-in-its-ongoing-phase-12a-clinical-trial-evaluating-vs-7375-first-two-monotherapy-dose-levels--cleared-with-no-dose-limiting-toxicities-reported-enrollment-initiated-for-vs-7375-in-combination-with-cetuximab-in-patients-with-advanced-kras-g12d-mutant-solid-tumors-including-colorectal-cancer
Verastem Reveals Preliminary Data From The...
10/23/2025 20:08:49

First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reportedPromising anti-tu...

reported-sunday-verastem-and-genfleet-report-41-overall-response-rate-915-tumor-reduction-and-967-disease-control-rate-with-gfh375-vs-7375-monotherapy-in-advanced-kras-g12d-mutant-pancreatic-cancer-at-600-mg-dose
Reported Sunday, Verastem And GenFleet Rep...
10/20/2025 07:42:48

GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more...

cantor-fitzgerald-assumes-verastem-at-overweight
Cantor Fitzgerald Assumes Verastem at Over...
10/16/2025 13:17:32

Cantor Fitzgerald analyst Eric Schmidt assumes Verastem (NASDAQ:VSTM) with a Overweight rating.

btig-reiterates-buy-on-verastem-maintains-20-price-target
BTIG Reiterates Buy on Verastem, Maintains...
09/09/2025 11:13:23

BTIG analyst Justin Zelin reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $20 price target.

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 21:06:15

verastem-oncology-announces-688-response-rate-for-kras-g12d-inhibitor-gfh375-in-nsclc-data-to-be-presented-at-wclc-2025
Verastem Oncology Announces 68.8% Response...
08/13/2025 20:32:32

GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 do...

rbc-capital-maintains-outperform-on-verastem-raises-price-target-to-13
RBC Capital Maintains Outperform on Verast...
08/08/2025 18:42:34

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $12 ...

verastem-q2-adj-eps-063-beats-074-estimate-sales-2137m-miss-5054m-estimate
Verastem Q2 Adj. EPS $(0.63) Beats $(0.74)...
08/07/2025 20:13:27

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.74) by 1...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

verastem-gets-fda-boost-for-new-oral-treatment-targeting-aggressive-pancreatic-tumors
Verastem Gets FDA Boost for New Oral Treat...
07/24/2025 11:34:37

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pa...

verastems-ovarian-cancer-trial-results-published-in-journal-of-clinical-oncology-titled-efficacy-and-safety-of-avutometinib--defactinib-in-recurrent-low-grade-serous-ovarian-cancer-verastems-avutometinib-combo-shows-31-overall-response-rate-in-ovarian-cancer-trial
Verastem's Ovarian Cancer Trial Results Pu...
07/11/2025 20:15:11

Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose ca...

verastem-oncology-announces-publication-of-updated-results-from-phase-12-frame-study-conducted-by-the-institute-of-cancer-research-london-and-the-royal-marsden-nhs-foundation-trust-in-nature-medicine
Verastem Oncology Announces Publication Of...
06/30/2025 20:05:25

FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), ...

rbc-capital-maintains-outperform-on-verastem-lowers-price-target-to-12
RBC Capital Maintains Outperform on Verast...
06/25/2025 14:38:58

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $16 ...

verastem-oncology-doses-first-patient-with-vs-7375-in-phase-12a-trial
Verastem Oncology Doses First Patient With...
06/24/2025 20:02:55

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
06/02/2025 17:06:00

nasdaq-edges-higher-ism-manufacturing-pmi-falls-in-may
Nasdaq Edges Higher; ISM Manufacturing PMI...
06/02/2025 16:49:43

whats-going-on-with-verastem-oncology-stock-on-monday
What's Going On With Verastem Oncology Sto...
06/02/2025 16:41:21

Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities ac...

verastem-oncology-announces-updated-data-from-dose-escalation-phase-of-the-phase-12-trial-of-gfh375-study-shows-orr-of-52-in-patients-with-pancreatic-ductal-adenocarcinoma-and-orr-of-42-with-non-small-cell-lung-cancer
Verastem Oncology Announces Updated Data F...
06/02/2025 13:42:49

In the study in China, GFH375 demonstrated an ORR of 52% in patients with pancreatic ductal adenocarcinoma and an ORR of 42% wi...

verastem-oncologys-phase-2-dose-level-1-shows-83-overall-response-rate-in-frontline-metastatic-pancreatic-ductal-adenocarcinoma
Verastem Oncology's Phase 2 Dose Level 1 S...
05/22/2025 21:57:11

Selected recommended Phase 2 dose: Dose level 1 demonstrated an ORR of 83% (10/12) in frontline metastatic pancreatic ductal ad...

verastem-reveals-updated-results-from-ramp-205-evaluating-avutometinib-plus-defactinib-in-combination-with-standard-of-care-chemotherapy-in-frontline-metastatic-pancreatic-ductal-adenocarcinoma
Verastem Reveals Updated Results From RAMP...
05/22/2025 21:05:27

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION